Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC).
暂无分享,去创建一个
P. Jänne | A. Shaw | L. Crinò | Paul D. Smith | C. Barrios | J. R. Pereira | J. Vansteenkiste | G. Jeannin | F. Franke | L. Grinsted | V. Zazulina | I. Smith